.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,235,248

« Back to Dashboard

Details for Patent: 7,235,248

Title:Pharmaceutical compositions comprising cyclosporins
Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2-Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.
Inventor(s): Hauer; Birgit (Lahr, DE), Meinzer; Armin (Buggingen, DE), Posanski; Ulrich (Freiburg, DE), Richter; Friedrich (Wachenheim/Weinstrasse, DE)
Assignee: Novartis AG (Basel, CH)
Filing Date:Oct 02, 2002
Application Number:10/263,164
Claims:1. An oral pharmaceutical composition comprising about 5 to about 25% by weight of a cyclosporin, about 0.5 to about 90% by weight of a propylene glycol hydrophilic component, about 0.5 to about 90% by weight of a lipophilic component and about 0.5 to about 90% by weight of a hydrophilic surfactant, all weight percents being based on the total weight of the composition, the relative proportion of said cyclosporin, hydrophilic component, lipophilic component and hydrophilic surfactant being such that upon dilution of said composition with adequate water, an oil-in-water microemulsion having an average particle size of less than about 0.15 microns is spontaneously formed, provided that the cyclosporin is not cyclosporin A.

2. The composition according to claim 1 wherein the average particle size is less than about 0.1 microns.

3. The composition according to claim 2 wherein the average particle size is from about 0.015 microns to less than about 0.1 microns.

4. The composition according to claim 1 wherein the dilution with water is to a ratio of 1 part by weight of composition to 1 part by weight of water.

5. The composition according to claim 1 comprising about 2 to about 45% by weight of lipophilic component, based on the total weight of the composition.

6. The composition according to claim 1 comprising about 20 to about 90% by weight of hydrophilic surfactant, based on the total weight of the composition.

7. The composition according to claim 1 comprising about 0.5 to about 90% by weight of hydrophilic component, about 2 to about 45% by weight of lipophilic component and about 20 to about 90% by weight of hydrophilic surfactant, all weights based on the total weight of the composition.

8. The composition according to claim 1 wherein the hydrophilic surfactant is selected from the group consisting of polyoxyethylene glycolated natural vegetable oil, polyoxyethylene glycolated hydrogenated vegetable oil, polyoxyethylene-sorbitan-fatty acid ester and polyoxyethylene fatty acid ester.

9. The composition according to claim 8 wherein the hydrophilic surfactant is a polyoxyethylene glycolated natural vegetable oil.

10. The composition according to claim 8 wherein the hydrophilic surfactant is a polyoxyethylene glycolated hydrogenated vegetable oil.

11. The composition according to claim 8 wherein the hydrophilic surfactant is a polyoxyethylene-sorbitan-fatty acid ester.

12. The composition according to claim 11 wherein the polyoxyethylene-sorbitan-fatty acid ester is selected from the group consisting of polyoxyethylene(20)sorbitanmonolaurate, polyoxyethylene(20)sorbitanmonopalmitate, polyoxyethylene(20)sorbitanmonostearate, polyoxyethylene(20)sorbitanmonooleate, polyoxyethylene(20)sorbitantristearate, polyoxyethylene(20)sorbitantrioleate, polyoxyethylene(4)sorbitanmonolaurate, polyoxyethylene(4)sorbitanmonostearate and polyoxyethylene(5)sorbitanmonooleate.

13. The composition according to claim 8 wherein the hydrophilic surfactant is a polyoxyethylene fatty acid ester.

14. The composition according to claim 1 further comprising ethanol.

15. The composition according to claim 1 wherein the cyclosporin is present in an amount of from 5 to 15 weight percent.

16. The composition according to claim 1 wherein the weight ratio of cyclosporin to hydrophilic surfactant is from about 1:1 to about 1:10.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc